Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging EvidenceHelgi Thor Hjartarson, Thomas Sejersen|Drug Design Development and Therapy|2022Cited by 57
Cancer Risk in Patients With Muscular Dystrophy and Myotonic DystrophyCarolina Maya‐González, Ann Nordgren, Fulya Taylan et al.|Neurology|2024Cited by 7